Owkin signs AI drug deal with Boehringer
AI firm Owkin has signed a licensing agreement with Boehringer Ingelheim to accelerate drug discovery for cancer and immunology. The partnership grants the drugmaker access to Owkins research platform and patient data network. Financial terms of the pact were not disclosed.
Xurve View
Insights:
Xurve View
Owkin has signed an AI drug discovery licensing deal with Germany-based Boehringer Ingelheim, gaining access to its research platform to accelerate treatments for oncology and immunology. The agreement expands Owkin's growing portfolio of pharma partnerships, following pacts with ASTRAZENECA PLC and SANOFI earlier in the year. The collaboration aims to leverage artificial intelligence to streamline target prioritization and data generation.
